Latest Gossamer Bio News & Updates

See the latest news and media coverage for Gossamer Bio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gossamer Bio

Clinical-stage biopharmaceutical company developing therapies for pulmonary hypertension

gossamerbio.com

Headquarters: San Diego, United States
Founded year: 2017
Company type: Public company
Number of employees: 125–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Gossamer Bio

In short: Gossamer Bio announced plans for a September 2026 NDA filing for seralutinib and reacquired full global rights following a Phase 3 miss.

Company announcements

July 27 Gossamer Bio

Gossamer Bio announces FDA update and reacquires seralutinib rights

The company plans to submit an NDA for seralutinib in PAH in September 2026, reacquired worldwide rights from Chiesi, and reported cash of $57 million.

June 17 Gossamer Bio

Gossamer Bio announces final tender results for exchange offer

The exchange offer for $181M in existing notes closed early, with $18.9M remaining outstanding.

June 3 Gossamer Bio

Gossamer Bio announces early tender results for exchange offer

90.526% of existing convertible notes tendered, early settlement expected June 4, with new notes and equity issued.

June 2 Gossamer Bio

Gossamer Bio extends early tender date for exchange offer

The company moved the early tender deadline to June 2, 2026, with settlement on June 4, 2026.

Media coverage

July 30 PHA Canada

Seralutinib Update: U.S. Approval Filing Planned

Back in March, we noted that Gossamer Bio’s phase 3 clinical trial of seralutinib (a drug for pulmonary arterial hypertension and pulmonary hypertension associated with...

July 28 Citeline

Gossamer’s Seralutinib NDA Plans Intact After FDA Clears Filing Path

After months of regulatory uncertainty following its Phase III PROSERA study's missed statistical threshold, the FDA's feedback on seralutinib is a shot in the arm...

July 28 Yahoo Finance

Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment

The plans follow a "productive" pre-application meeting with the U.S. Food and Drug Administration, the company said Monday, when shares closed almost 47% higher in...

July 27 Sina Finance

Gossamer Bio receives positive FDA feedback, plans to submit PAH new drug application in September

Clinical-stage biopharmaceutical company Gossamer Bio today announced a series of significant regulatory, strategic, and corporate updates. After a productive Pre-NDA Type B meeting with the U.S. FDA and receiving the official meeting minutes, the company is proceeding as planned to advance its core drug seralutinib for the treatment of pulmonary arterial hypertension towards a New Drug Application, with a target submission date of September 2026. According to the meeting minutes, the FDA characterized the statistical significance and magnitude of treatment effect observed in the Phase III PROSERA study as a review issue rather than a filing obstacle. Based on this...

Never miss news about Gossamer Bio

Track Gossamer Bio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gossamer Bio competitors & trending companies

Browse news for competitors to Gossamer Bio and other trending companies.